A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer
- 1 August 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (3) , 366-369
- https://doi.org/10.1038/bjc.1998.500
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Immunotherapy of metastatic renal cell cancerAnnals of Oncology, 1996
- Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.Journal of Clinical Oncology, 1996
- Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinomaAnnals of Oncology, 1996
- Renal cell carcinomaCurrent Opinion in Oncology, 1996
- Medical treatment of advanced renal cell carcinoma: present options and future directionsCancer Treatment Reviews, 1996
- Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors.1996
- Interferon‐alpha and survival in renal cell cancerBritish Journal of Urology, 1995
- Survival After Phase II Treatment of Advanced Renal Cell Carcinoma with Taxol or High-Dose Interleukin-2Journal of Immunotherapy, 1993
- Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.Journal of Clinical Oncology, 1993
- A Comparison of 2 Modes of Administration of Recombinant Interleukin-2: Continuous Intravenous Infusion Alone Versus Subcutaneous Administration plus Interferon Alpha in Patients with Advanced Renal Cell Carcinoma.Cancer Biotherapy, 1993